Tandem Diabetes Care, Inc. a global insulin delivery and diabetes technology company, announced FDA clearance for Tandem Mobi today. The U.S. Food and Drug Administration (FDA) cleared the device as the world’s first and only tubeless insulin pump with automated insulin delivery (AID) and up to 7 days of wear. This tubeless insulin pump gives people with diabetes a new way to manage their condition.
A new Tandem Mobi tubeless cartridge and infusion set drive this change. Together, they convert the current Tandem Mobi pump into a tubeless device. As a result, users can change infusion sites less often. Moreover, they keep the life-changing benefits of Control-IQ+ advanced hybrid closed-loop technology.
The FDA now clears the Tandem Mobi insulin pump for both tubeless and tubed insulin infusion. Therefore, it is the only pump that lets users choose the wear option that best meets their needs.
John Sheridan, president and chief executive officer, explained the thinking behind the design.
“The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to 7 days of wear1,” said John Sheridan, president and chief executive officer. “This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology.”
Tandem Mobi Tubeless Launch Timeline and Compatibility
Tandem plans a full commercial launch of the new tubeless cartridge and infusion set in the first half of 2027. The launch will take place in the United States. Importantly, customers with an in-warranty Tandem Mobi do not need a new insulin pump. Existing Tandem Mobi pumps already work with the new tubeless infusion set and cartridge. In addition, Tandem will contact eligible customers. The company will explain how to access the sets and cartridges once they become available.
It will be distributed through pharmacies. Tandem Mobi Tubeless infusion sets and cartridges will only be available through the pharmacy for customers with pharmacy benefits. Today, Tandem estimates pharmacy coverage for Tandem Mobi customers is about 50% of insured lives in the United States. Moreover, the company anticipates ongoing growth pre-launch and during 2027.
Overall, the clearance adds a tubeless wear option to the Tandem Mobi pump. Users get tubeless automated insulin delivery, less frequent site changes, and the proven Control-IQ+ technology in one system.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com